AN
47
3
SJM
19
5
V
56
2
NDAQ
56
3
GME
57
2
RRC
50
4
VRTX
62
10
PEG
50
4
CA
16
3
DIS
52
3
BIIB
38
2
PNC
55
3
NRG
67
8
MMM
30
2
FOXA
63
3
YUM
43
5
SLB
45
4
KR
44
4
EMR
62
14
FDX
41
11
AN
47
3
SJM
19
5
V
56
2
NDAQ
56
3
GME
57
2
RRC
50
4
VRTX
62
10
PEG
50
4
CA
16
3
DIS
52
3
BIIB
38
2
PNC
55
3
NRG
67
8
MMM
30
2
FOXA
63
3
YUM
43
5
SLB
45
4
KR
44
4
EMR
62
14
FDX
41
11
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
27

ASND
Ascendis Pharma AS

Last Price:
127.98
Seasonality Move:
11.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $288.75M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-6.00
Price / Book: 0

Profitability

EPS (TTM): -9.34900
Net Income (TTM): $-530.29M
Gross Margin: $240.69M
Return on Equity: 0%
Return on Assets: -60.1%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 5 years for ASND is 83.36%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 99.13% of Gross Profit Margin.
  • The Research & Development expenses have been 155.02% of Revenue.
  • The Interest Expense is -9.15% of Operating Income.
  • The Net Earning history of ASND is -180.51% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 4 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -2.09
Current Ratio: 0.74
Quick Ratio: 0.4

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ASND Technical Analysis vs Fundamental Analysis

Sell
27
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?